Bruker Corporation (NASDAQ:BRKR) was upgraded by analysts at J P Morgan Chase & Co from an “underweight” rating to a “neutral” rating in a report released on Friday, November 3rd, MarketBeat.com reports. The firm presently has a $28.00 target price on the medical research company’s stock. J P Morgan Chase & Co’s target price points to a potential downside of 13.55% from the company’s current price.
Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Bruker Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Wells Fargo & Company downgraded shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $24.00 price objective on shares of Bruker Corporation in a research note on Tuesday, September 26th. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Thursday, July 6th. Finally, Barclays PLC reissued an “equal weight” rating and issued a $30.00 price objective (up previously from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $29.64.
Bruker Corporation (NASDAQ:BRKR) traded up $0.56 on Friday, reaching $32.39. The company had a trading volume of 657,700 shares, compared to its average volume of 632,791. Bruker Corporation has a 12 month low of $21.03 and a 12 month high of $35.16. The stock has a market capitalization of $5,130.00, a price-to-earnings ratio of 27.20, a P/E/G ratio of 2.69 and a beta of 1.05. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65.
Bruker Corporation (NASDAQ:BRKR) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Bruker Corporation had a return on equity of 25.83% and a net margin of 8.85%. The business had revenue of $435.60 million during the quarter, compared to analyst estimates of $415.45 million. During the same quarter in the previous year, the business earned $0.32 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. analysts predict that Bruker Corporation will post 1.19 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://weekherald.com/2017/11/15/bruker-corporation-brkr-upgraded-to-neutral-at-j-p-morgan-chase-co.html.
In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the transaction, the vice president now owns 60,524 shares in the company, valued at $1,813,904.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 35.20% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. raised its position in shares of Bruker Corporation by 8.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 667,400 shares of the medical research company’s stock worth $19,855,000 after purchasing an additional 50,800 shares during the last quarter. Zions Bancorporation acquired a new position in shares of Bruker Corporation during the 3rd quarter worth about $119,000. Janus Henderson Group PLC acquired a new stake in Bruker Corporation in the 3rd quarter valued at about $2,576,000. PEAK6 Investments L.P. acquired a new stake in Bruker Corporation in the 3rd quarter valued at about $381,000. Finally, Magnetar Financial LLC acquired a new stake in Bruker Corporation in the 3rd quarter valued at about $749,000. Hedge funds and other institutional investors own 65.47% of the company’s stock.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.